4 Results for "

VEGF-induced retinal leakage

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "VEGF-induced retinal leakage" in MCE Product Catalog:

Dammarenediol II
Dammarenediol II
0 Images
Cat. No.: HY-N3677
CAS No.: 14351-29-2
Category:  

Triterpenes other families Boswellia freerana Terpenoids Plants

Target:  

OGT Akt mTOR GSK-3 Reactive Oxygen Species (ROS) Apoptosis PARP MDM-2/p53

Dammarenediol II is a ginsenoside precursor . Dammarenediol II reduces the activity of O-GlcNAc transferase (OGT) and downregulates the global O-GlcNAcylation level. Dammarenediol II inhibits the phosphorylation of Akt, mTOR and GSK3β. Dammarenediol II inhibits human carboxylesterase activity, VEGF-induced ROS production, stress fiber formation and vascular endothelial cadherin disruption. Dammarenediol II promotes cell apoptosis (apoptosis), increases the levels of cleaved PARP1 and p53, and inhibits retinal microvascular leakage. Dammarenediol II can be used in studies related to liver cancer and diabetic retinopathy .
loading...
    loading...
View All Sizes
Cenupatide
Cenupatide
0 Images
Cat. No.: HY-P1615
CAS No.: 1006388-38-0
Synonyms: UPARANT
Target:  

Transmembrane Glycoprotein Formyl Peptide Receptor (FPR) VEGFR Akt STAT JNK p38 MAPK ERK NF-κB Apoptosis Integrin

Research Areas:  

Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Cenupatide (UPARANT) is a uPAR and FPR antagonist with anti-angiogenic, anti-inflammatory, and vascular barrier regulatory activities, as well as high stability and resistance to enzymatic degradation in blood/plasma. Cenupatide blocks the uPAR-FPR interaction, reduces VEGF-induced phosphorylation levels of AKT, VEGFR-2, STAT3, JNK, p38 MAPK, ERK1/2, and NF-κB p65, and inhibits αvβ3 integrin activation. Cenupatide suppresses endothelial cell migration, invasion, tube formation, and angiogenic signaling pathways, restores tight junctions and blood-retinal barrier integrity, reduces pro-inflammatory marker levels, and inhibits apoptosis. Cenupatide reduces retinal neovascularization, renal fibrosis, and vascular leakage, and restores visual function in preclinical models. Cenupatide is applicable to research related to retinopathy, diabetic complications, ocular diseases, cancer, and inflammatory diseases .
loading...
    loading...
View All Sizes
EYE1118
EYE1118
0 Images
Cat. No.: HY-184142
CAS No.: 3037217-73-2
Target:  

VEGFR

Research Areas:  

Cardiovascular Disease Neurological Disease

EYE1118 is an orally active, photoactivatable VEGFR2 inhibitor without acute hepatotoxicity. EYE1118 mediates light-enhanced inhibition via azide-functionalized receptor binding, and can utilize light-guided targeting to regulate its biodistribution in vivo. EYE1118 effectively inhibits angiogenesis, endothelial cell migration, VEGF-induced retinal leakage, and the size of choroidal neovascular lesions. EYE1118 has been applied in studies related to age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization .
loading...
    loading...
View All Sizes
EYE1090
EYE1090
0 Images
Cat. No.: HY-184141
CAS No.: 3037217-70-9
Target:  

VEGFR

Research Areas:  

Neurological Disease

EYE1090 is an orally active VEGFR2 inhibitor with an IC50 of 3 nM. EYE1090 inhibits angiogenesis, endothelial migration, VEGFR2-induced retinal leakage, and reduces choroidal neovascularization lesion size in mice. EYE1090 can be used for the research of age-related macular degeneration, diabetic retinopathy, choroidal neovascularization .
loading...
    loading...
View All Sizes
Assay Types